A drug that isn't approved anywhere is about to become the most-discussed molecule in obesity medicine. It's worth understanding before the marketing arrives.

Retatrutide is the first "triple G" agonist — it hits the GIP, GLP-1, and glucagon receptors, once weekly. The first two you already know; they drive the appetite-and-satiety mechanism behind the whole class. The glucagon arm is the differentiator. It adds an energy-expenditure and hepatic-fat lever on top of appetite suppression, and that's why the numbers look the way they do.

I put the whole evidence base on one reference card — the Retatrutide Cheat Sheet. Three pages, free, download below. Here's what matters most.

TRIUMPH-1: 80 weeks, 2,339 adults with obesity or overweight and no diabetes. Mean weight loss from baseline:

At 12 mg, 45.3% of patients lost 30% or more of their body weight — 37.9% at 9 mg, 15.3% at 4 mg. In a 104-week extension, participants with BMI ≥35 who escalated to their maximum tolerated dose reached up to roughly 30% at two years. Those are among the largest weight-loss magnitudes reported in the incretin class to date.

One honest caveat on those figures: they're topline, treatment-regimen estimand, from a company press release. Detailed results are pending ADA 2026 and peer review. Real, but not yet fully published — read them as a strong signal, not a closed case.

The glucagon arm shows up beyond weight. In phase 2, retatrutide produced an 86% mean reduction in liver fat — a dedicated MASLD trial is pending. TRIUMPH-4, in obesity plus knee osteoarthritis, showed 28.7% weight loss and reductions in knee pain.

Then on July 23, two more readouts landed. TRIUMPH-2, in type 2 diabetes with obesity (n=1,152), delivered 20.8% weight loss and a 1.5-point A1C drop at 12 mg, against 4.0% and −0.2 on placebo. That is the number to sit with: roughly 21% in a population that typically loses less than people without diabetes. TRIUMPH-3, in severe obesity with established cardiovascular disease (n=1,949), showed 22.6% at 12 mg versus 3.2% on placebo, alongside risk-factor movement at 12 mg — hsCRP −51.2%, triglycerides −37.0%, systolic pressure −9.3 mmHg. Renal, MASLD, and chronic low back pain trials are still reading out.

Here's the thing: most coverage will get it backward. The headline is the glucagon receptor — but watch lean mass and cardiovascular outcomes before you watch the weight-loss number.

Two reasons. First, lean-mass preservation is still an open question for retatrutide specifically, and a focus of upcoming data — the same muscle conversation the rest of the class has had, not yet answered here. Second, weight loss is a surrogate. TRIUMPH-3 did report MACE, but events ran below projection and the intervals are wide: MACE-5 HR 0.82 (0.55–1.22), MACE-3 HR 1.12 (0.64–1.96). That is underpowered and non-definitive — do not read it in either direction. A properly powered cardiovascular outcomes trial still has not reported, and until it does, a drug can post a spectacular scale number and still need to prove it prevents events.

And tolerability tracks the dose. GI events — nausea, vomiting, diarrhea — dominate and run somewhat higher than earlier in the class. In TRIUMPH-1, discontinuation rose with dose: 4.1% at 4 mg to 11.3% at 12 mg, versus 4.9% on placebo. It ran higher in the sicker cohorts — 13.5% at 12 mg in TRIUMPH-3 — and was non-monotonic in TRIUMPH-2 (3.8%, 11.6%, 7.7%), so read "dose-dependent" as a trend rather than a rule. The glucagon arm also warrants monitoring heart rate and glycemia.

Retatrutide is not approved anywhere. Lilly plans to file a BLA with the FDA in Q1 2027. Everything above is trial data, not a labeling. Anyone selling it to you today is operating outside the approved supply chain — which is its own conversation, and not a good one.

Five positive phase 3 studies now sit behind that filing, covering obesity, knee osteoarthritis pain, and obstructive sleep apnea. What is still missing is what matters most: lean-mass data, durability after stopping, and a properly powered cardiovascular outcomes trial. If those hold, this is the drug that pushes the ceiling of the class into bariatric-surgery territory. If they don't, the scale number was never the whole story. Either way, you'll want the reference.

Mechanism, the full efficacy table, the comorbidity trials, the safety breakdown, the dosing snapshot from the trial protocol, and the readouts still to come — three pages, every number sourced to the trial.

Talk soon,
Michael

Michael Albert, MD — Board-Certified Obesity Medicine Physician

This is educational and not medical advice. Retatrutide is investigational and not FDA-approved; nothing here recommends obtaining or using it. Individual decisions about obesity therapy should be made between a patient and their clinician.

Following the latest GLP-1 trials? The live tracker is here: https://substance-over-noise.beehiiv.com/trials

Was this forwarded to you? Subscribe free: https://substance-over-noise.beehiiv.com/subscribe